
What are the limits in the fight against obesity? Ozempic owner disappoints the market
Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new slimming drug CagriSema
Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new slimming drug CagriSema
The Yale-educated physician joined the company in 2020 to help people find credible health information online and answer common questions that users ask on the platform
As more pharmaceutical companies make inroads in the weight loss market, the two firms saw their shares fall more than 10% in the last month
Emblaveo has been developed by Pfizer and AbbVie, with the help of the EU and the United States, and is effective against some multidrug-resistant infections that have been untreatable until now
Karuna’s top asset is KarXT, an experimental antipsychotic with a promising novel mechanism. It’s currently being reviewed by the USFDA for treatment of schizophrenia in adults
It’s also been increasingly difficult for medical providers to get benzathine penicillin injections — the main medical weapon against congenital syphilis — because of supply shortages
The Food and Drug Administration decision opens the newest shots from Moderna and Pfizer and its partner BioNTech to most Americans even if they’ve never had a coronavirus vaccination
The drugs include the blood thinner Eliquis, diabetes treatment Jardiance and eight other medications
Experts say the damaged plant could lead to a supply disruption while Pfizer figures out next steps. Those could include shifting production to another location
A company statement said all employees were safely evacuated and accounted for
Drug companies like BMS, GSK and Amgen face revenue losses from patent expirations
European countries are negotiating with pharmaceutical companies to avoid accumulating unused doses
The pharmaceutical giant said Monday that it will pay $229 per Seagen share
The company accuses its competitors of copying its messenger RNA technology without its permission